Products for Research Use Only
RegisterLogin

JNJ-26481585

CAT: 0421-27632-3Size: 50 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0421-27632-3Size:50 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Background
Quisinostat, also known asJNJ-26481585, is an orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor JNJ-26481585 inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of tumor cell division; and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Compared to some first generation HDAC inhibitors, JNJ-26481585 may induce superior HSP70 upregulation and bcl-2 downregulation.
Description
JNJ-26481585, also known as Quisinostat, is a potent pan-HDAC inhibitor. JNJ-26481585 induces histone acetylationand inhibits cancer cell proliferation.
CAS Number
875320-29-9
Purity
≥ 98% by HPLC
Solubility
Soluble in DMSO
Molecular Formula
C21H26N6O2
Shipping Conditions
Room Temperature (continental US) or Gel Packs
Storage Conditions
Store at or below –20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.
Calculated Molecular Weight
394.5 Da

Alternative Products

CatalogName
TRC-J211333-100MGJNJ-26481585
TRC-J211334-100MGJNJ-26481585-d3
A10492-10JNJ-26481585 10mg
MBS578630Quisinostat (JNJ-26481585)
A10492-100JNJ-26481585 100mg
A10492-50JNJ-26481585 50mg
A10492-5JNJ-26481585 5mg
A10492-2JNJ-26481585 (Quisinostat) 2mg
MBS579391Quisinostat (JNJ-26481585) 2HCl

Popular Products